Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
Authors:
Open Access
- 29 May 2012
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 107 (1) , 137-142
Abstract
Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.Keywords
This publication has 27 references indexed in Scilit:
- Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpressionMolecular Cancer, 2011
- Mesothelin expression correlates with prolonged patient survival in gastric cancerJournal of Surgical Oncology, 2011
- Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferationCarcinogenesis, 2011
- Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapyLung Cancer, 2010
- High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaBritish Journal of Cancer, 2009
- Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3Molecular Cancer Research, 2008
- Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerMolecular Cancer Therapeutics, 2008
- Mesothelin targeted cancer immunotherapyEuropean Journal of Cancer, 2008
- Anti–Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor XenograftsClinical Cancer Research, 2007
- Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous CarcinomaClinical Cancer Research, 2006